Hemophagocytic Lymphohistiocytosis Unknown Status Phase 3 Trials for Etoposide (DB00773)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

IndicationStatusPhase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)Unknown Status3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03742115
Etoposide in the First-line Treatment of Adult EBV-HLHTreatment
NCT02912702
L-DEP as an Initial Treatment for EBV-HLHTreatment
NCT04077905
Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.Treatment
NCT02631109
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic LymphohistiocytosisTreatment